Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm curious about Intracoastal Capital's beneficial ownership statement filed for Baudax, in the week before Dale sold his Baudax shares, which was one day ahead of the Baudax delisting. Will this somehow translate into a gateway for Humanigen to acquire an interest in Tera-Immune through Intracoastal Capital?
https://www.sec.gov/cgi-bin/browse-edgar?company=baudax&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
I just think that Humanigen has a real interest in Tera-Immune's novel Treg-based cell therapies for autoimmune diseases.
https://www.baudaxbio.com/news-and-investors/press-releases/detail/267/baudax-bio-acquires-teraimmune-inc
The timing is worth noting. If there is a connection between these transactions, maybe we'll find out on or before Monday, when the market is closed. It wouldn't be the first time the company announced major news on a day when the market is closed.
If they would have filed chapter 7 Bankruptcy, I would have been 100% in agreement with you. However, they filed Chapter 11 Bankruptcy which keeps the Share structure intact. If they wanted to destroy the current shareholders, they would have filed for Chapter 7 Bankruptcy which would have wiped the stock out as well.
Even if they do nothing our OS is 119 million shares. For a shell alone this will be worth pennies at very minimum. With the Bankruptcy behind them they will be debt free and this will be very clean going forward.
I too would be very happy with $1, but if we make it to $1 then we are most likely going much higher than that.
I've had a couple of friends who have been telling me about all of the benefits of opening a Roth IRA for quite some time now. My problem was that I have been trading to supplement my pension income. So, a Roth kept me from taking gains right away. Therefor I have not been interested. However, in 2023 I turned 52 and I am getting closer to that 59 1/2.
Then after printing my 1099 forms from my one E-trade account and having 164 pages of trades just on one account that I will have to hand over to my tax guy which he isn't going to be too happy about. I decided maybe I can do some of this day trading for my future and not have to worry about all of the paperwork.
Roth IRA trades do not need to be reported like they do on a regular brokerage. Hopefully this will be a way for me to have some fun trading without the hassle of paperwork and hopefully build Wealth for myself and my family. I probably should have done this a long time ago.
I would like to put 1 million shares of my HGEN in my Roth IRA while it's cheap, but lakers is probably correct about this as he has been doing this much longer than me. I probably won't be able do that transfer from a Non-Roth Brokerage account, and there is no way to liquidate HGEN and then buy it back in the ROTH while it trades on the expert market. so, I will just hold my shares in the regular brokerage account.
You are Absolutely 100% Correct and I wouldn't mind one bit on paying my fair share of capital gains taxes. The Roth IRA for me would be more for "self-control" for me not selling this too early like $1 or $2 dollars per share when it could go over a hundred. Being in a Roth IRA knowing I can't touch it keeps me in check from selling too early. Plus, this will set my family up in case something happens to me.
Welcome to the room, LuckyWanderer21.
I saw shares trade for over $200 per share during the first recall of the company's loaned shares. Of course, price wasn't sustained at that level. Prices dropped as the brokerages bought-in their clients who were short. This was in the November/December 2015 time frame. The chart linked below doesn't quite reflect share prices that high, but I think that's because the chart doesn't reflect data from all of the worldwide exchanges. The highest price I see during the referenced time frame was just over $174.
https://www.google.com/search?q=kalobios+stock+price+history&oq=kalobios+stock+price+history&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigAdIBCjE4Njg1ajBqMTWoAgCwAgA&sourceid=chrome&ie=UTF-8
But I know what prices I saw, up to about $248, as I recall. And those prices were initially charted.
Of course it seems far-fetched. But, in my opinion, the company has been steadily loaning shares in preparation of a second recall of their loaned shares, which I eagerly await.
But, if you have reason to think management has no plan for individual shareholders, please enlighten us. On second thought, don't bother.
Sorry. currently, there’s no plan for individual shareholders, and the stock might vanish. I’m curious, why do some think it’s feasible? $200 per share… Is that really realistic? Personally, it seems far-fetched.
I’d be happy even with $1 per share, but even that seems unlikely. The company doesn’t appear to be doing anything for individual shareholders.
If Jay is right about $200 a shares you shouldn’t be worried about paying your fair share of long term capitol gains taxes on your nearly $1billion profit off a less than $1k investment!
Using a Roth for these speculative stocks is the way to go. Let me share my experience. I've had two scenarios. My accounts are with Schwab. Also, I have been funding, over the years, Roth's for two of my adult children. Now, for my own accounts, I was able to move actual shares owned, from my IRA to my Roth IRA. However, I could not do it online. I had to call Schwab and request it from a live person to make the move. For my adult children, I could not transfer shares from any of my accounts to theirs. I had to put in cash and buy the shares in their accounts. I could transfer cash from my regular brokerage account to theirs after I signed a letter approving it and allowing Schwab to keep it on file for future years. So in some years, I would sell the particular shares in my brokerage account, wait for settlement, transfer it, and buy the shares in their account.
You are most likely right about this. I will let you know if I am able to make the transfer of 1 million shares of my HGENQ from my Brokerage account into my Roth IRA account through E-trade. It would be nice as HGENQ is only worth $400 for 1 million shares at today's prices.
If not it's no big deal as I am holding 4,100,000 shares. So, if cowtown jay is correct about this I will be paying a lot of taxes. LOL :)
I am 99% sure it has to be cash if a new Roth and no other Roth.
I don't see why it has to come from another stock Roth as long as it doesn't exceed the $8000 for 2024? But I will find out soon enough though as I am going to call them tomorrow and see if I can do it.
Through E-trade I set the Stock Roth up along with option trading permission. From what I can see I can transfer internally from my E-trade Brokerage account to my Roth Brokerage account. But then again, the account is still being processed and I cannot transfer anything until it's completed.
You very well maybe correct about me not being able to transfer an existing holding into the Roth Brokerage account.
I won't know until the account is fully active.
I do know I wouldn't dare sell any of my position as I couldn't get it back being that its trading on the expert market.
In 2024 it went from $7500 to $8000. However a million shares of HGEN is only worth $400 at the current pps.
Welcome to the room, lakers17. Could prove to be perfect timing.
I am pretty sure you can't do that. You have to sell and fund the Roth with cash as a contribution for 2023 until April 15th 2024 or for 2024.. Only way you could is in a stock Roth to another stock Roth. $8,000 $8,000 max cash for 2024 if 50 or over. $7,000 for under 50 for 2024. 2023 was $7,500/$6.500.
Good move!
My only chance at making real money is if we have a successful short squeeze during the recall of our loaned shares, and I am fortunate at getting filled on my sell orders. I may just bite the tax bullet so that my daughters won't have to worry about that. But I don't know yet what I'll do.
I opened a Roth IRA Yesterday. My hopes are that I can transfer 1 million shares of HGENQ from my E-Trade account into the IRA for when it appreciates that it will be tax free on those million shares. Plus knowing I can't touch it will keep me from selling it too early. :)
I love our double today even though it was only at .0004.
Yes, I think you have several accounts you manage for your family, with $50 sell prices. I hope the bid gets run up, and those orders fill, maybe with a premium price.
You go, Jay! I have several high-$ sell GTC orders myself. We shall see.
Some lucky Bastard in Canada got 100,000 shares at .0004! :)
Um...I didn't hear you. Can you say it again?
I've been curious about how management would time the upcoming events. Specifically, I wondered if management would begin to roll-out our immediate course change before or after the bankruptcy was concluded. Now we know.
Some years ago, I was disappointed that a number of prospective investors were denied purchases of shares because we were over-subscribed. I had hoped that management would accommodate them, which they did not do. But that was the right business decision at that time, just as concluding the bankruptcy before announcing new developments is the right business decision at this time.
I'm truly not concerned in the least bit. If short sellers were students of what this management team has done by capitalizing on the design of their share structure, they would have saved themselves the pending circumstance of being forced to buy-in their borrowed shares by submitting a bid to the bankruptcy judge. Now, however, I will be happy to provide shares at $200 for them to cover their short positions.
If Big Pharma deduced that Humanigen has created partnerships with Novavax and Gracell, and that we have a pathway to regulatory approval, even if initially overseas, they, too, would have submitted bids for the company. But Gilead's Daniel O'Day, and others, couldn't quite envision that, and will lose substantial market share in the near term, as a consequence.
Whoa I post that and the pps doubles
lol!
Hope you’re right, but no other bids doesn’t sound promising to me. I would be happy to be wrong about that!
I think our success is more of a sure shot, than a long shot. I think management anticipated events to unfold as they have, and they planned accordingly and brilliantly. All the pieces are coming together, and I hope that the results of management's efforts will prove life-changing for shareholders, and life-saving for future patients. I'm not surprised or worried about any of the developments we are seeing.
I always felt the lenz was effective. But when there is a sale for the company and no takers followed by a sale of the company assets and no takers, one has to believe the drug does not work and the data is suspect
Yep sounds like we are hosed if the judge hands Lenz over to Durant for $2 million.
I do appreciate Jays optimism since that seems like the only long shot chance that shareholders will benefit, but I don’t see that as Durrant doing it out of the kindness of his heart!
"In sum, the Stalking Horse Agreement is not just the highest
and best offer for the Acquired Assets, it is the only offer, and is the result of over a year of marketing efforts and months of independent and good-faith negotiations. The Sale to the Stalking Horse Bidder should be approved as a result"
https://document.epiq11.com/document/getdocumentbycode?docId=4292711&projectCode=HUM&source=DM
Back to HGEN….well there isn’t anything positive so I guess that’s why we are discussing immigration instead.
Investors are really sweet on Gracell, as we see a third Beneficial Ownership filing for them on Feb 14th, this one, "...subject to a Beneficial Ownership Blocker (as defined below)," which limited the acquisition to a total 9.99% stake in the company.
https://www.sec.gov/Archives/edgar/data/1346824/000110465924023999/tm246065d12_sc13ga.htm
Are these investors reacting to Gilead/Kite's announcement two weeks ago of FDA approval to "speed up" their CAR-T turnaround time from 16 days to 14 days?
https://www.fiercepharma.com/manufacturing/gileads-kite-wins-fda-nod-new-car-t-manufacturing-process-speed-yescarta-turnaround
This compares to Gracell's recently enhanced (with lenz?) "...FasT CAR solution, preparation time can be cut to 24 hours, significantly reducing production cost and waiting time."
https://www.pharmasources.com/industryinsights/54541.html
Almost as true as HGENQQQQQQ trading again. Insanity is an understatement
"In sum, the Stalking Horse Agreement is not just the highest
and best offer for the Acquired Assets, it is the only offer, and is the result of over a year of marketing efforts and months of independent and good-faith negotiations. The Sale to the Stalking Horse Bidder should be approved as a result"
https://document.epiq11.com/document/getdocumentbycode?docId=4292711&projectCode=HUM&source=DM
It appears that Dale may have dumped his Baudax shares. I'll continue monitoring the Baudax filings, in case we see Tera-Immune news.
https://www.sec.gov/Archives/edgar/data/1178179/000101359424000171/baudax13ga1-02142024.htm
I hate speaking about ethnicities, especially when my natural-born daughters are Amer-Asian. But we know one illegal Chinese-owned biolab has already been discovered operating in California. And I admit that I am concerned about this influx of illegal immigrants, and their objectives in coming here. I think it is in our national security interest to have lenz approved as a vaccine adjuvant, as well as a respiratory tract therapeutic.
appreciate. fingers and toes all crossed for any value. cheers to share holders.
Hi, Jim,
Welcome to the room, and to Ihub.
If Durrant had filed a Chapter 7 bankruptcy, shareholders would have been wiped out.
But Durrant filed a reorganization bankruptcy under Chapter 11, which allows for the share structure to remain intact.
Here are a couple of articles about our previous bankruptcy, when the company was known as Kalobios, before restructuring.
https://moxreports.com/kbio-infinity-squeeze/
https://www.globenewswire.com/news-release/2017/07/27/1063782/0/en/KaloBios-To-Change-Company-Name-To-Humanigen-Inc.html
I'm looking for management to recall their loaned shares once again, and to cause yet another massive short squeeze.
Isn't HGEN bankrupt? how do HGEN share holders have any chance at success? I was under impression that assets would be sold off and HGEN stock worth nothing now.
I'm not surprised by your comment. You have generally been more skeptical than I have been. But who hasn't been? It's been a tough road for shareholders.
But, it really is hard to comprehend the scope of our pending success. I understand that. It will be unparalleled. I've got faith in management, and in lenz. Even Ifab looks promising.
I just don't see a departure from the path management has been on since the company was established. I remain very optimistic and excited.
I’m thinking Durrant is taking his toys (Lenz) and leaving HGEN shareholders with a dirty playpen. Maybe the unsecured creditors claim will stop him from doing so and he will have to make better arrangements for the mess he has at HGEN?
Or he can take it all and walk away with “promises” under no legal obligation.
I think we are hosed.
You did miss something as we all did.
Maybe I missed somethings that you are aware of. Please show me, for example, why management has an obligation to discuss developments regarding Novavax.
Management HAS an obligation!! thats the disconnect
I track SEC filings everyday for Humanigen, Baudax, Gracell, and Novavax. That list was developed over the years for reasons I disclosed, as I thought each company represented an opportunity for Humanigen.
But those are my opinions. They do not place an obligation on management to comment. I am not a spokesman for the company. At best, I express what I think management may be doing, and I think they WILL comment on each of those companies as our transition continues.
This is pubic information. Why wouldn’t HGENQqqqqqq management keep shareholders updated on what they were doing? Because your theories are not true
Gracell sees a second amended 13G filed yesterday.
https://www.sec.gov/Archives/edgar/data/1826492/000121390024013387/ea193538-13ga1vivo_gracell.htm
Of course, the biggest bang for Durrant's drug development program dollars, isn't even mentioned in my earlier post.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173802006
I have assumed that Novavax has been evaluating the use of lenz with their covid vaccine. Durrant may intend on integrating lenz with an anti-viral and polyclonal antibodies, in a fully developed cocktail, in accordance with our patent. A good amount of investment dollars seem to be flowing into Novavax now. How exciting!!
Two more amended 13G's filed today. One each for Gracell and Novavax.
https://www.sec.gov/cgi-bin/browse-edgar?company=gracell&match=starts-with&filenum=&State=&Country=&SIC=&myowner=exclude&action=getcompany
https://www.sec.gov/Archives/edgar/data/102909/000110465924021584/tv01573-novavaxinc.htm
Durrant appears open to future discussions with unsecured creditors at a time and place TBD. I'm not worried about it way way or the other.
No other bidders…I don’t know man this ain’t looking so good for unsecured creditors imo. Hope I’m wrong
Followers
|
326
|
Posters
|
|
Posts (Today)
|
6
|
Posts (Total)
|
43073
|
Created
|
01/31/13
|
Type
|
Free
|
Moderators DTGoody cowtown jay |
Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms. As a leader in GM-CSF pathway science, we believe that we have the ability to transform CAR-T therapy and a broad range of other T-cell engaging therapies, including both autologous and allogeneic cell transplantation. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. Clinical correlative analysis and pre-clinical in vivo evidence points to GM-CSF as the key initiator of the inflammatory cascade resulting in CAR-T therapy’s side-effects. Pre-clinical in vivo data on the neutralization of GM-CSF using antibody or gene KO indicates that it is not required for CAR-T cell activity. Our strategy is to continue to pioneer the use of GM-CSF neutralization and GM-CSF gene knockout technologies to improve efficacy and prevent or significantly reduce the serious side-effects associated with CAR-T therapy.
We believe that our GM-CSF pathway science, assets and expertise create two technology platforms to usher in next-generation CAR-T therapies. Lenzilumab, our proprietary Humaneered® anti-GM-CSF immunotherapy, has the potential to be used in combination with any FDA-approved or development stage CAR-T therapy, as well as in combination with other cell therapies such as HSCT, to make these treatments safer and more effective. In addition, our GM-CSF knockout gene-editing platform has the potential to create next-generation CAR-T therapies that may inherently avoid any efficacy/toxicity linkage, thereby potentially preserving the benefits of the CAR-T therapy while altogether avoiding its serious and potentially life-threatening side-effects.
The company’s immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company’s proprietary Humaneered® anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the use of lenzilumab with Yescarta®, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. The company is also developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, T cell engaging, and immunotherapy treatments to break the efficacy/toxicity linkage including the prevention and/or treatment graft-versus-host disease (GvHD) in patients undergoing allogeneic HSCT. The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline.
June 15, 2020
Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Hospitalized Patients With COVID-19 Pneumonia
https://clinicaltrials.gov/ct2/show/NCT04351152
Anti-GM-CSF antibodies expected to show better effect in Covid-19 than cytokine-specific targets
July 27, 2020
https://discoverysedge.mayo.edu/2021/06/22/cancer-to-covid-19/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |